Drug Discovery Segment to Dominate Europe Human Liver Models Market During 2021–2028    

In the case of COVID-19, Europe is highly affected especially France and Russia. The current COVID-19 outbreak has not caught EU-funded research off guard. The MSCA of the European Commission supports outstanding researchers in finding solutions to challenges posed by the novel coronavirus disease COVID-19 and other infectious diseases. Also, to facilitate the launch of clinical trials relating to COVID-19, authorities have allowed expedited authorization procedures for the initial assessment of authorization requests. However, remerging waves of COVID-19 have mixed impacts on the market due to the closing of clinical trials sites. As per Phesi's analysis from September 2020, global clinical trial sites suspensions peaked in June, and after an initial drop, had risen again and had a significant impact on phase 2 and 3 trials. With increased global economic uncertainty across sectors, 2021 is expected to be challenging for most clinical development organizations worldwide. Clinical research is vital to developing new treatments and improved understanding of disease, and COVID-19 presents many challenges. The Governments in the region are planning a safe and sustainable restart of non-COVID trials. As of September 2020, the NIHR Clinical Research Network data has shown that non-COVID studies are restarting, with 45% of studies open to recruitment. Additionally, organoids are being used by researchers around the EuroStemCell partnership. For example, an international group of scientists, including researchers from IMBA – Institute of Molecular Biotechnology of the Austrian Academy of Sciences, slowed SARS-CoV-2 infection in organoids, demonstrating the potential blocking effect of a drug already in clinical trials. The researchers are undergoing various research to manage the COVID-19 outbreak. Thus, increased research activities will lead to vital opportunities for the market.

The Europe human liver models market has been segmented based on type, application, end user, and country. Based on type, the market is segmented into liver organoids, liver-on-a-chip, 2D models, 3D bioprinting, and others. The liver organoids segment dominated the market in 2020 and liver-on-a-chip segment is expected to be fastest growing during forecast period. Based on application, the market is segmented based on drug discovery, educational, and others. The drug discovery segment dominated the market in 2020 and same segment is expected to be fastest growing during forecast period. Based on end user, the market is segmented into pharmaceutical and biotechnology companies, research institutes, and others. The pharmaceutical and biotechnology companies segment dominated the market in 2020 and same segment is expected to be fastest growing during forecast period.  Based on country, the market has been segmented into the UK, Germany, France, Italy, Spain, and rest of Europe.

BioIVT; CELLINK; CN Bio Innovations; Cyprio; Emulate, Inc.; InSphero; Kerafast; Kirkstall; MIMETAS BV; and THERMO FISHER SCIENTIFIC INC. are among the leading companies in the Europe human liver models market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Emulate, Inc. announced the close of an $82 Thousand Series E financing round led by existing investor Northpond Ventures with additional participation from Perceptive Advisors. With this investment, Emulate has raised nearly $225 Thousand to date.